CapsulesClinical Overview
Ilaprazole (10mg gastro-resistant) and Domperidone (30mg prolonged-release) combines a next-generation substituted benzimidazole PPI with a prokinetic antiemetic. Ilaprazole exhibits an extended plasma elimination half-life (~7-8 hours vs 1-2 hours for older PPIs), producing deeper, longer nocturnal gastric acid control and superior intragastric pH > 4 holding time. Domperidone ensures enhanced gastric emptying and lower esophageal sphincter competency. Indicated for nocturnal acid breakthrough, severe erosive esophagitis, and refractory GERD with nausea.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily in the morning, 30 to 60 minutes before breakfast with water. Swallow the capsule whole.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Headache, dizziness, diarrhea, dry mouth, abdominal pain. Rare/Severe: QTc prolongation, hyperprolactinemia, hypomagnesemia, and interstitial nephritis.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in patients with cardiac conduction disturbances, hypokalemia, or prolactinomas. Chronic PPI therapy warrants periodic bone density and magnesium evaluations.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or gastrointestinal treatment recommendations. Always consult a registered gastroenterologist or qualified medical practitioner before initiating, altering, or discontinuing any gastrointestinal medication or digestive therapy.
Domperidone Tablets 10 mg
Domperidone Tablets (10mg) and Suspension (5mg/5ml) is a peripheral dopamine D2 receptor antagonist antiemetic and prokinetic on the WHO Model List framework. Because it does not readily cross the blood-brain barrier, it acts primarily at the chemoreceptor trigger zone (outside the blood-brain barrier) and gastrointestinal tract, stimulating upper GI motility, increasing LES pressure, and accelerating gastric emptying. Indicated for relief of symptoms of nausea and vomiting of various etiologies, and diabetic gastroparesis.
Domperidone Suspension 5mg per 5ml
Domperidone Tablets (10mg) and Suspension (5mg/5ml) is a peripheral dopamine D2 receptor antagonist antiemetic and prokinetic on the WHO Model List framework. Because it does not readily cross the blood-brain barrier, it acts primarily at the chemoreceptor trigger zone (outside the blood-brain barrier) and gastrointestinal tract, stimulating upper GI motility, increasing LES pressure, and accelerating gastric emptying. Indicated for relief of symptoms of nausea and vomiting of various etiologies, and diabetic gastroparesis.
Omeprazole 20mg + Domperidone 10mg Capsules
Omeprazole (20mg gastro-resistant) and Domperidone (10mg/30mg sustained-release) is a cornerstone fixed-dose PPI and prokinetic combination on the WHO Model List framework. Omeprazole irreversibly suppresses gastric acid secretion by inhibiting parietal cell H+/K+-ATPase. Domperidone blocks peripheral dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) and gastrointestinal tract, stimulating gastric motility and preventing acid reflux. Indicated for gastroesophageal reflux disease, non-ulcer dyspepsia, and peptic ulcer disease accompanied by nausea, fullness, or vomiting.
Rabeprazole 20mg (Enteric Coated) + Domperidone 30mg (Sustained Release) Capsules
Rabeprazole Sodium (20mg enteric-coated) and Domperidone (10mg/30mg sustained-release) is a rapid-onset PPI and prokinetic combination. Rabeprazole has a higher pKa (~5.0) than other PPIs, allowing faster activation at higher pH and achieving rapid, potent inhibition of gastric H+/K+-ATPase pumps from the first dose. Domperidone provides dopamine D2 antagonism to enhance lower esophageal sphincter tone and accelerate gastric emptying. Indicated for erosive esophagitis, GERD, hypersecretory conditions, and dyspeptic symptom complexes (nausea, postprandial fullness, acid regurgitation).